Palatin Technologies (PTN) Total Non-Current Liabilities (2015 - 2024)
Palatin Technologies' (PTN) quarterly Total Non-Current Liabilities came in at $10.0 million in Q3 2024, down 29.17% YoY from $14.1 million in Q4 2023, and down 7.92% on a QoQ basis from $10.9 million in Q2 2024.
Palatin Technologies (PTN) Total Non-Current Liabilities (2015 - 2024) Analysis & Trends
Palatin Technologies (PTN) has 10 years of Total Non-Current Liabilities data on file, last reported at $10.0 million in Q3 2024.
- Quarterly Total Non-Current Liabilities fell 29.17% year-over-year to $10.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $10.0 million (down 29.17% YoY) and the FY2024 annual result came in at $10.9 million, down 39.04% from the prior year.
- Total Non-Current Liabilities slipped to $10.0 million in Q3 2024, from $10.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $23.4 million in Q4 2023 to a low of $3.4 million in Q1 2020.
- A 5-year average of $12.3 million and a median of $11.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Total Non-Current Liabilities surged 489.5% — and 2024, when it tumbled 39.04%.
- Tracing PTN's Total Non-Current Liabilities over 5 years: stood at $8.1 million in 2020, then surged by 82.41% to $14.8 million in 2021, then fell by 19.51% to $11.9 million in 2022, then jumped by 96.71% to $23.4 million in 2023, then slumped by 57.31% to $10.0 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $10.0 million (Q3 2024), $10.9 million (Q2 2024), and $8.8 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 9.32 Bn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 9.99 Mn |
| Jun 30, 2024 | 10.85 Mn |
| Mar 31, 2024 | 8.80 Mn |
| Dec 31, 2023 | 23.41 Mn |
| Sep 30, 2023 | 14.11 Mn |
| Jun 30, 2023 | 17.81 Mn |
| Mar 31, 2023 | 12.24 Mn |
| Dec 31, 2022 | 11.90 Mn |
| Sep 30, 2022 | 16.45 Mn |
| Jun 30, 2022 | 16.94 Mn |
| Mar 31, 2022 | 12.74 Mn |
| Dec 31, 2021 | 14.78 Mn |
| Sep 30, 2021 | 10.60 Mn |
| Jun 30, 2021 | 11.41 Mn |
| Mar 31, 2021 | 11.02 Mn |
| Dec 31, 2020 | 8.11 Mn |
| Sep 30, 2020 | 13.56 Mn |
| Jun 30, 2020 | 4.88 Mn |
| Mar 31, 2020 | 3.36 Mn |
| Dec 31, 2019 | 1.37 Mn |